CinRxPharma

A Hub-And-Spoke BiotechPortfolio CompanyDone Differently

CinPressa PharmaCinDome PharmaCinCor PharmaCinPressa PharmaCinDome PharmaCinCor PharmaCinPressa PharmaCinDome PharmaCinCor Pharma

CapitalExpertiseExecution

Too many promising medicines fail to reach patients due to development hurdles rather than scientific limitations. At CinRx Pharma, we bridge that gap, propelling high-potential therapeutics forward with strategic capital, deep expertise, and infrastructure built on insights from thousands of clinical programs.

The CinRx operating model

Our structure empowers innovation through efficiency. We establish asset-focused portfolio companies, known as ‘CinCos,’ designed to operate within a streamlined management framework. This allows each asset to advance rapidly without the traditional burdens of early-stage biotech building.

Discover our model

  1. Centralized execution engine

    Cross-functional experts power every program from one shared team.

  2. Frictionless capital deployment

    Resources flow dynamically to the assets that need them at inflection points.

  3. Embedded clinical infrastructure

    Medpace partnership for global trial execution and regulatory pathways.

Our portfolio

We pursue medicines that address significant unmet patient needs and have the potential to meaningfully improve outcomes. Our rigorous identification and diligence process informs a highly selective acquisition strategy, resulting in a differentiated portfolio across multiple disease areas.

Newsroom

Stay up to date with the latest updates across the CinRx portfolio of companies.

  1. CinDome Pharma

    CinDome Pharma Announces Completion of Enrollment in the envisionGI Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis

    CinDome announced the completion of patient enrollment in its envisionGI Phase 2 clinical study evaluating deudomperidone (CIN-102) for the treatment of idiopathic gastroparesis.

    Read story
  2. CinDome Pharma

    CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

    CinDome announced enrollment completion in its envision3D Phase 2 trial evaluating deudomperidone (CIN-102) for the treatment of diabetic gastroparesis.

    Read story
  3. CinDome Pharma

    CinDome Pharma Announces First Patient Dosed in Clinical Trial of Deudomperidone (CIN-102)

    CinDome announced the dosing of the first patient in its clinical trial of deudomperidone (CIN-102) for the treatment of idiopathic gastroparesis.

    Read story
More news
Connect

Let's advance medicine, together

Whether you're a clinical investigator, a potential partner, or considering joining our team - we'd like to hear from you.

Start a conversationPartnering inquiries